SC6: ASSEMBLING AN EFFECTIVE TOOLBOX OF EXPRESSION SYSTEMS TO SUPPORT YOUR DRUG DISCOVERY EFFORTS

TUESDAY, JANUARY 21 | 5:45 - 8:45 PM (DINNER PROVIDED)

Aqua 310B

This course will discuss the systems necessary to support the expression of both traditional (mAbs) and next-generation formats of proteins to support all aspects of drug discovery. This includes therapeutic candidates, assay reagents, immunogens, and proteins for structural studies.

Detailed Agenda

5:45 pm Welcome and Opening Remarks

5:55 Insect Expression Systems

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

6:45 Dinner Break

7:00 Mammalian Expression Systems

Henry Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

8:00 Implementing Eukaryotic Expression Systems

Richard Altman, Field Application Scientist, Protein Expression, Biosciences Division, Life Science Solutions, Thermo Fisher Scientific

8:45 Close of Short Course

Instructors:

Richard Altman, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific

Rich Altman has 30 years of experience in protein expression and production. In early 2019, he joined Thermo Fisher Scientific as a Field Application Scientist.  Previously, he worked for several pharmaceutical companies, including Amgen, Alexion, Bayer, and Upjohn, on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

Henry Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years, he has worked as a principal scientist and now in product development and portfolio management for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.

Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on providing production of Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on Ras biology including structural biology, biophysics, and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his PhD in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.

Back to Short Courses